Synthesis and Anti‐Inflammatory Activity Evaluation of Benzoxazole Derivatives as New Myeloid Differentiation Protein 2 Inhibitors
Chemistry & Biodiversity · 2023-06 · 20 (6)
DOI: 10.1002/cbdv.202201145 ↗At a glance
Journal article in Chemistry & Biodiversity, published online on 2023-05-10. Written by Huiying Bai and 7 co-authors. Institution: School of Pharmaceutical Science, Shanxi Medical University, Shanxi, 030001, P. R. China. Major MEDLINE topics: Anti-Inflammatory Agents, Benzoxazoles. Cited 9 times so far (Crossref); 16 references. Funded by: National Natural Science Foundation of China, Shanxi Province Science Foundation for Youths, Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Based on Chronic Inflammation.
Abstract (original language)
Myeloid differentiation protein 2 (MD2), a key TLR4 adaptor protein for sensing LPS, plays an important role in inflammatory process and has been identified as a promising target for the treatment of a variety of inflammatory diseases. In our study, a series of benzoxazolone derivatives were synthesized, characterized and tested for anti‐inflammatory activity in vitro . The compounds 3c , 3d and 3g demonstrated the greatest anti‐inflammatory activity against IL‐6 with IC 50 values of 10.14±0.08, 5.43±0.51 and 5.09±0.88 μM, respectively. Furthermore, the bis‐ANS displacement assay revealed that these compounds competitively inhibited the binding between the probe bis‐ANS and the MD2 protein. The most active compound 3g , revealed a directly bind with MD2 protein via Arg90 binding and a dissociation constant value of 1.52×10 −6 mol L −1 as determined by the biological layer interference (BLI) assay. Our finding suggested that compounds 3g could be a promising lead compound as MD2 inhibitor for further anti‐inflammatory agent development.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Pharmaceutical Science, Shanxi Medical University, Shanxi, 030001, P. R. China.
- Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, Shanxi University of Traditional Chinese Medicine, Shanxi, 030619, P. R. China.
Funding
- National Natural Science Foundation of China
- Shanxi Province Science Foundation for Youths
- Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Based on Chronic Inflammation
- Shanxi Scholarship Council of China
- Shanxi Graduate Education
Cite
APA
Bai, H., Cao, Z., Meng, S., Ge, R., Ban, S., Zhang, Y., Tang, L., & Li, Q. S. (2023). Synthesis and Anti‐Inflammatory Activity Evaluation of Benzoxazole Derivatives as New Myeloid Differentiation Protein 2 Inhibitors. Chemistry & Biodiversity, 20(6). https://doi.org/10.1002/cbdv.202201145
Vancouver
Bai H, Cao Z, Meng S, Ge R, Ban S, Zhang Y, et al. Synthesis and Anti‐Inflammatory Activity Evaluation of Benzoxazole Derivatives as New Myeloid Differentiation Protein 2 Inhibitors. Chemistry & Biodiversity. 2023;20(6). doi:10.1002/cbdv.202201145
BibTeX
@article{Bai2023,
author = {Bai, Huiying and Cao, Zhen and Meng, Sha and Ge, Rui and Ban, Shurong and Zhang, Yuanlin and Tang, Li and Li, Qing-Shan},
title = {Synthesis and Anti‐Inflammatory Activity Evaluation of Benzoxazole Derivatives as New Myeloid Differentiation Protein 2 Inhibitors},
journal = {Chemistry & Biodiversity},
year = {2023},
volume = {20},
number = {6},
doi = {10.1002/cbdv.202201145}
}
EUVIMED